Table 3.
Demographic characteristics and distribution for the type of reporter, suspected drug, seriousness, outcome, and causality assessment involving quinolones recognized in the Campania spontaneous reporting system from January 2001 to April 2019.
| Variable | Level | Cases of musculoskeletal or neurological or psychiatric disorders (N=87) |
Total (N=442) |
|---|---|---|---|
| Gender | Female Male Not available |
44 (50.6) 43 (49.4) - |
259 (58.6) 179 (40.5) 4 (0.9) |
| Age | Median (IQR) | 57 (41–74) | 55 (36–70) |
| Seriousness | Serious–other clinically significant condition Serious–death Serious–significant or permanent disability Serious–hospitalization Serious–life threatening Not defined Not serious |
14 (16.1) 1 (1.1) 6 (6.7) 14 (16.1) 1 (1.1) 3 (3.4) 48 (55.2) |
57 (12.9) 2 (0.5) 8 (1.8) 66 (14.9) 9 (2.0) 11 (2.5) 289 (65.4) |
| Outcome | Death Improvement Unchanged clinical condition Not available Recovered Resolution with sequelae |
1 (1.1) 25 (28.7) 14 (16.1) 15 (17.2) 31 (35.6) 1 (1.1) |
3 (0.7) 175 (39.6) 25 (5.7) 52 (11.8) 176 (39.8) 11 (2.5) |
| 1° Generation 2° Generation 3° Generation 4° Generation |
Cinoxacin Pipemidic acid Norfloxacin Ciprofloxacin Lomefloxacin Ofloxacin Rufloxacin Levofloxacin Moxifloxacin Pefloxacin Prulifloxacin |
2 (2.3) 2 (2.3) - - 34 (39.1) 28 (32.2) 3 (3.4) 2 (2.3) 1 (1.1) 46 (52.9) 41 (47.1) 5 (5.7) - 5 (5.7) 5 (5.7) |
10 (2.3) 4 (0.9) 4 (0.9) 2 (0.5) 195 (44.1) 179 (40.5) 12 (2.7) 3 (0.7) 1 (0.2) 226 (51.1) 206 (46.6) 18 (4.1) 2 (0.5) 11 (2.5) 11 (2.5) |
| Reporter | Physicians Pharmacist Other health care professional Patient/Citizen or other nonhealthcare professional figure |
44 (50.6) 15 (17.2) 11 (12.6) 17 (19.5) |
242 (54.8) 78 (17.6) 76 (17.2) 46 (10.4) |
| Causality | Possible Probable Doubt |
58 (66.7) 28 (32.2) 1 (1.1) |
261 (59.0) 180 (40.7) 1 (0.2) |
| Number of reported suspected drugs | >1 1 |
10 (11.5) 77 (88.5) |
66 (14.9) 376 (85.1) |